MedTrace Logo

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

NCT00137826 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2011-12-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether the combination of the investigational drugs Avastin and Tarceva are effective in patients with mesothelioma who have previously been treated with chemotherapy.

Conditions

Interventions

DRUG

Erlotinib

Taken orally once daily. Participants may continue on study treatment until disease progresses or they experience serious side effects.

DRUG

Bevacizumab

Given intravenously over 30-90 minutes, on day 1 of each 21-day cycle. Participants may continue on study treatment until disease progresses or they experience serious side effects.

Sponsors & Collaborators

Principal Investigators

  • Pasi A Janne, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2007-03-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00137826 on ClinicalTrials.gov